Advanced Life Sciences Holdings, Inc. (ADLS) SEC Filing 10-Q Quarterly report for the period ending Tuesday, June 30, 2009

Exhibit 99.1

Advanced Life Sciences Announces Second Quarter 2009 Financial Results and Financial Outlook

CHICAGO, IL, August 11, 2009/PRNewswire/: —

The net loss allocable to common shareholders for the three months ended June 30, 2009 was $2.6 million or ($0.06) per share compared to a net loss allocable to common shareholders of $3.4 million or ($0.09) per share for the three months ended June 30, 2008.  The decrease in the net loss is due to decreased costs involved in the clinical development of the Company’s lead compound, Restanza™ (cethromycin).

The Company ended the second quarter of 2009 with cash and cash equivalents totaling $1.0 million.  Cash used during the quarter was approximately $2.9 million.

“Advanced Life Sciences today is focused on continuing to pursue approval for Restanza in community acquired pneumonia by complying with the FDA’s recommendations concerning next steps that can lead to registration,” said Michael T. Flavin, Ph.D., chairman and chief executive officer of Advanced Life Sciences. “Based on the agency’s recent communication with the Company, we anticipate that an additional well-controlled clinical study designed to demonstrate efficacy in a more severe CAP population will likely be required for the approval of Restanza. We intend to work closely with the agency to confirm this understanding and design and establish a protocol under a Special Protocol Assessment. We are working on these clinical plans with Wyeth, our development and commercialization partner in the Asia Pacific region, and will also continue to pursue additional collaborations. At the same time, we are also continuing to advance Restanza as a biodefense agent against anthrax, plague and tularemia in our collaborative work with the U.S. government, which funds our biodefense development program.”

Operating Expense Analysis

·                  Research and development expenses were $1.3 million for the three months ended June 30, 2009 compared to $1.7 million for the three months ended June 30, 2008.

·                  Selling, general and administrative expenses totaled $1.7 million, approximately the same amount as the second quarter of last year.

Business Outlook for 2009

·                  Work with the FDA and Wyeth to develop a new clinical protocol to further demonstrate Restanza’s efficacy in CAP;

·                  Pursue a meeting with the FDA relative to establishing a Special Protocol Assessment for development of Restanza in CAP;

·                  Advance negotiations with prospective U.S. and E.U. partners for the development and commercialization of Restanza;

-MORE-